ASH 2017 | CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM

Katja Weisel

An exciting update on the CASTOR trial was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. Here, Katja Weisel, MD, of University of Tübingen, Tübingen, Germany, shares the results that were presented from the long-term follow-up of the CASTOR trial (NCT02136134), a comparative Phase III study that assessed the effects of administering daratumumab combined with bortezomib and dexamethasone, compared with bortezomib and dexamethasone alone, in patients with relapsed and/or refractory multiple myeloma (MM).

Share this video